Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different

R Rana1, J Dalal1, D Singh1

  • 1MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., 2nd Floor, Nanotechnology Building, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India.

Vaccine
|April 25, 2015
PubMed

Insights

Developing a cost-effective Haemophilus influenzae type b (Hib) conjugate vaccine is crucial. This study optimized Hib capsular polysaccharide (PRP)-tetanus toxoid (TT) conjugates, finding low molecular weight versions more immunogenic in rats.

Area of Science:

  • Vaccinology
  • Microbial immunology
  • Bioconjugation chemistry

Background:

  • Haemophilus influenzae type b (Hib) capsular polysaccharide conjugates are vital for childhood vaccines.
  • High costs limit access to essential Hib conjugate vaccines for vulnerable populations.

Purpose of the Study:

  • To develop a cost-effective and more immunogenic Hib conjugate vaccine.
  • To optimize the preparation of Hib capsular polysaccharide (PRP)-tetanus toxoid (TT) conjugates.

Main Methods:

  • Controlled periodate oxidation introduced aldehyde groups into Hib polysaccharide.
  • Reductive amination covalently linked polysaccharide to hydrazide-derivatized tetanus toxoid.
  • Polysaccharide chain length was reduced to 100, 50kDa, or 10kDa oligosaccharides.

Main Results:

  • Hib PRP-TT conjugates were successfully prepared with polysaccharide-to-protein ratios of 0.25-0.5 (w/w).
  • Conjugates exhibited low free saccharide levels (<10%).
  • Immunization of rats elicited specific anti-PRP antibodies, with low molecular weight conjugates showing superior immunogenicity.

Conclusions:

  • Optimized PRP-TT conjugates offer a promising strategy for more affordable and potent Hib vaccines.
  • Low molecular weight Hib polysaccharide-tetanus toxoid conjugates demonstrate enhanced immunogenicity.
  • This approach could improve global access to essential Hib vaccination.

Related Concept Videos

Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
94
Conjugated Proteins02:50

Conjugated Proteins

Simple proteins and protein complexes contain only amino acids. In contrast, many other proteins, called conjugated proteins, covalently bond with non-protein moieties.
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
29.9K
Formation of Lipopolysaccharides01:19

Formation of Lipopolysaccharides

Lipopolysaccharides (LPS) are crucial components of the outer membrane of Gram-negative bacteria, serving both structural and functional roles. It contributes to membrane stability and protects bacteria from host immune responses. LPS is composed of three major regions—lipid A, a core oligosaccharide, and an O antigen. The biosynthesis and assembly of LPS involve a highly coordinated set of enzymatic reactions and transport mechanisms. Additionally, LPS is recognized as an endotoxin,...
998